Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 36.5%, free cash flow fell 174.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow NTRA
Natera, Inc. (NTRA) EV/Sales
As of 16 October 2026, Natera, Inc. (NTRA) trades at a EV/Sales of 20.5×. Over the past ten years it has ranged from 0.0× (February 2016) to 24.5× (February 2021); the current reading is higher than 97% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.3× | 17.68% |
| FY2024 | 11.3× | 84.88% |
| FY2023 | 6.1× | 53.92% |
| FY2022 | 4.0× | (68.51%) |
| FY2021 | 12.6× | (35.05%) |
| FY2020 | 19.4× | 189.17% |
| FY2019 | 6.7× | 123.49% |
| FY2018 | 3.0× | 23.47% |
| FY2017 | 2.4× | (3.87%) |
| FY2016 | 2.5× | 318.45% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 14.1× | 27.86% |
| Mar 2026 | 11.0× | (16.93%) |
| Dec 2025 | 13.3× | 31.25% |
| Sep 2025 | 10.1× | (11.28%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LH Labcorp Holdings Inc. compare | 2.2× |
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| IQV IQVIA Holdings Inc. compare | 3.4× |
| A Agilent Technologies, Inc. compare | 6.9× |
| MTD Mettler-Toledo International, Inc. compare | 8.4× |
| ILMN Illumina, Inc. compare | 9.0× |
| IDXX IDEXX Laboratories, Inc. compare | 9.8× |
| WAT Waters Corporation compare | 10.2× |
| NTRA Natera, Inc. | 20.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)